title: Bone marrow with gelatinous transformation associated with residual disease in imatinib mesylate-treated chronic myelogenous leukaemia (CML).
authors.forename: Beenu
authors.initials: B
authors.lastname: Thakral
authors.forename: Bryce
authors.initials: B
authors.lastname: Higa
authors.forename: Girish
authors.initials: G
authors.lastname: Venkataraman
authors.forename: Milind M
authors.initials: MM
authors.lastname: Velankar
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001707:Biopsy, Needle; D001853:Bone Marrow / Q000473:pathology*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D018365:Neoplasm, Residual; D010198:Pancytopenia / Q000188:drug therapy / Q000473:pathology; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate